BioNxt Solutions Settles Debt with Share Issuance

Vancouver, BC – February 27, 2026 – BioNxt Solutions Inc. (CSE:BNXT) has completed a debt settlement by issuing 6,008,883 common shares, resolving $2,704,000 in outstanding liabilities. The transaction addresses amounts owed to creditors not connected to the company, stemming from $2,600,000 in principal and $104,000 in accrued interest on 8% convertible debentures originally issued in December 2022.

Debt Settlement Details

The shares issued for the debt settlement were valued at $0.45 each. In addition to settling creditor debt, BioNxt Solutions issued 300,444 shares to Canaccord Genuity Corp. At $0.63 per share as consideration for their assistance with the settlement process. FinanzWire reported on the completion of this transaction.

Background on Convertible Debentures and Finder’s Fees

The settled debt originated from a non-brokered private placement of convertible debentures closed on December 7, 2022, which raised $2,808,000. Accesswire details that the debentures carried an 8% annual interest rate, payable semi-annually, and matured two years from the issue date.

As part of the December 2022 offering, Canaccord Genuity Corp. Received a cash fee of $224,640 and 432,000 finder warrants. The CSE filing indicates each warrant allows the holder to purchase one common share at an exercise price of $0.52 for 24 months from the issuance date.

Statutory Hold Period

All shares issued in the recent debt settlement are subject to a four-month statutory hold period, as mandated by Canadian securities law. This restricts the shares from being traded during this period.

Looking Ahead

This debt settlement represents a step towards strengthening BioNxt Solutions’ financial position. The company intends to use the resulting capital for general working capital purposes.